Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis

SK chemicals

Status and phase: Completed; Phase 3

Conditions: Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis

Treatments: Drug: nalfurafine hydrochloride (TRK-820); Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01513161

TRK-820_PRU_III_2007

Details and patient eligibility

About

The purpose of this study is to determine whether nalfurafine hydrochloride is effective and safe in the treatment for conventional-treatment-resistant pruritus in patients receiving hemodialysis.

Enrollment: 104 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

[At the time of obtaining the consent form]

• Chronic renal failure patients who regularly receive hemodialysis three times a week and are not likely to have a serious treatment change or acute symptoms during the study period

• Patients who received both of the drug pruritus treatments in section 1 and 2 below within one year before the day of singing consent form

  1. Systemic therapy of more than two consecutive weeks depending on antihistamine or antiallergic drugs falling under "prescription drugs with indication of pruritus" (oral drugs, injections, etc.)
  2. Local therapy depending on "prescription drugs with indication of pruritus" (ointment, etc.) or a moisturizer prescribed by a doctor (topical preparation, etc.)

• Patients for whom all the conventional pruritus treatments in section (2) are not enough

• Patients aged 20 years or older at time of signing the consent form

[At the time of enrollment]

• Patients whose VAS scores are measured both after breakfast and dinner for five days or more of the last 7 days of the predose observation period and whose mean of whichever the higher VAS scores after breakfast or dinner is ≥50 mm
• Patients whose whichever the higher VAS score after breakfast or dinner for the last 7 days during the preliminary observation day (measured VAS score if one is missing) is more than ≥20 mm for five days or more
• Patients who are judged to have pruritus both during the day and at night for more than two days based on the Shiratori's severity criteria assessed by the subject at days of fifth and sixth hemodialysis and the day of hemodialysis after the completion of the predose observation period, and whose whichever the higher pruritis score measured during the day or at night is 3 (moderate) for two days or more

Exclusion criteria

• Patients with malignant tumor
• Patients with depression, schizophrenia or dementia as complications
• Patients who currently have Child-pugh class B or C hepatic cirrhosis as complications
• Patients with clinically significant hepatic or cardiovascular diseases which cannot be controlled by diet or drug therapy
• Patients who currently have the following heart diseases: life-threatening arrhythmia; unstable angina or myocardiac infarction within 6 months; PCI or CABG within 6 months; NYHA class III or IV congestive heart failure
• Patients with atopic dermatitis or chronic urticaria as complications
• Patients who are allergic to opioid drugs
• Patients with dependence on drug or alcohol
• Patients who received phototherapy for pruritus within one month before signing the consent form
• Patients who participated in the study of TRK-820 and received the study drug or who were already enrolled in this study
• Patients who participated in other clinical studies (including the ones using artificial kidney and medical equipment), and received the study drug or treatment with clinical equipment within one month before signing the consent form
• Pregnant women, lactating women and patients of childbearing potential who do not use contraceptive methods
• Patients who cannot report VAS scores by their own for any reason at the principal investigator or study personnel's discretion
• Patients whose complications or history can impact the results of this study at the principal investigator or subinvestisator's discretion
• Other patients who are not proper to participate in this study at the principal investigator or study personnel's discretion

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Factorial Assignment

Masking: Double Blind

---

104 participants in 3 patient groups, including a placebo group

TRK-820 5μg

Active Comparator group

Description:

Taking TRK-820 5μg(two 2.5μg capsules) by oral route once daily for 14 days

Treatment:

Drug: nalfurafine hydrochloride (TRK-820)

TRK-820 2.5μg

Active Comparator group

Description:

Taking TRK-820 2.5μg(one 2.5μg capsule \& one placebo capsule)by oral route once daily for 14 days

Treatment:

Drug: nalfurafine hydrochloride (TRK-820)

Placebo

Placebo Comparator group

Description:

Taking Placebo(two placebo capsule) by oral route once daily for 14 days

Treatment:

Drug: Placebo